GSK Patent Delays Doom Its Covid-Shot Suit, Pfizer, BioNTech Say

GlaxoSmithKline Plc revived decade-old patent applications it acquired from Novartis AG to claim that Comirnaty Covid-19 vaccines infringe them, Pfizer Inc. and BioNTech SE told a federal judge, denying the allegations and insisting their products comply with FDA regulations.

The five GSK patents are invalid, unenforceable, and aren’t infringed by multiple versions of Comirnaty, Pfizer and BioNTech said in counterclaims filed Wednesday in the US District Court for the District of Delaware. “It was not until the details of Pfizer and BioNTech’s Covid-19 vaccine became publicly available that GSK pursued the patent claims it now asserts against them,” according to ...